Post

• FDA approves Glaukos’ Epioxa as incision-free corneal disease treatment

  The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease …

  

• ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory

  Johnson & Johnson’s (J&J’s) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous …

  

• Infertility treatment amongst first drugs included on FDA’s new priority voucher scheme

  The US Food and Drug Administration (FDA) has selected the first products to be included on the Commissioner’s National Priority …

  

• FDA greenlight for Roche’s Alzheimer’s disease test sparks care paradigm shift

  The US Food and Drug Administration’s (FDA) recent clearance of Roche’s blood-based Alzheimer’s disease test will boost therapeutic intervention options …

  

• ESMO 2025: Eli Lilly’s Verzenio extends survival in high-risk early breast cancer

  Eli Lilly’s Verzenio (abemaciclib) boosted overall survival (OS) in the adjuvant breast cancer setting during a late-stage trial. In the Phase …

  

No more posts